Flowchart showing patient recruitment and outcomes:

- **Assessed for eligibility (n = 35)**
  - Excluded (n = 1)
    - Failed eligibility criteria (n = 1)
  - Randomised (n = 34)

**Cohort A** (masitinib plus cholinesterase inhibitor and/or memantine)
- **Allocated to masitinib-arm (n = 26)**
- **Received allocated intervention (n = 26)**
  - Start dose of 3 mg/kg/day (n = 12)
  - Start dose of 6 mg/kg/day (n = 14)

- **Premature discontinuation (n = 17)**
  - Adverse event (n = 9)
  - Protocol violation (n = 1)
  - Withdrawal of consent (n = 2)
  - Investigator death (n = 7)

- **On-going at week 24 (n = 9)**
- **Primary endpoint analysis* (n = 16)**

**Cohort B** (placebo plus cholinesterase inhibitor and/or memantine)
- **Allocated to placebo-arm (n = 8)**
- **Received allocated intervention (n = 8)**

- **Premature discontinuation (n = 2)**
  - Adverse event (n = 0)
  - Protocol violation (n = 1)
  - Withdrawal of consent (n = 0)
  - Investigator death (n = 1)

- **On-going at week 24 (n = 6)**
- **Primary endpoint analysis* (n = 6)**

---

*Week 12 data for closed study centre imputed using LOCF for week 24.